In Vitro Activity of Ceftolozane/Tazobactam and Imipenem/Relebactam in Clinical Isolates of Pseudomonas Aeruginosa and Enterobacterales Collected From Hematology and Oncology Patients (ACTHEON)

Emilio Bouza

Status

Unknown

Conditions

Hematology and Oncology

Ceftolozane/Tazobactam

Imipenem/Relebactam

Treatments

Drug: imipenem- relebactam

Drug: Ceftolozane/tazobactam

Study type

Observational

Funder types

Other

Industry

Identifiers

NCT04196608

MICRO.HGUGM.2019-008

Details and patient eligibility

About

The purpose of the ACTHEON Study is to evaluate the in vitro activity of ceftolozane-tazobactam, imipenem-relebactam and comparator agents (amoxicillin- clavulanate, piperacillin-tazobactam, ceftazidime, cefotaxime, cefepime, imipenem, meropenem, levofloxacin and amikacin; see list more details on page 7) against clinical isolates of P. aeruginosa and Enterobacterales prospectively collected from hematology and oncology patients with complicated intra-abdominal infections (cIAIs), complicated urinary infections (cUTIs), lower respiratory tract infections (LRTIs), and blood stream infections (BSIs) from 15 participating centers in Spain

Enrollment

1,005 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

P. aeruginosa isolates
Enterobacterales isolates

Exclusion criteria

Non P. aeruginosa isolates
Non Enterobacterales isolates

Trial design

1,005 participants in 2 patient groups

P. aeruginosa isolates

Description:

All isolates will be sent to the Central Laboratory, where identification will be confirmed by MALDI-TOF and susceptibility testing against ceftolozane/tazobactam, imipenem- relebactam and comparative agents will be performed

Treatment:

Drug: imipenem- relebactam

Drug: Ceftolozane/tazobactam

Enterobacterales isolates

Description:

Treatment:

Drug: imipenem- relebactam

Drug: Ceftolozane/tazobactam